New Jersey is currently home to 1653 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: Hunterdon Medical Center, Flemington, New Jersey
Conditions: Malignant Neoplasm
Register for Updates
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
NCT02848274
Recruiting
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Gender:
ALL
Ages:
All
Trial Updated:
10/01/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma
Register for Updates
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)
NCT06561360
Recruiting
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
Conditions: Hairy Cell Leukemia
Register for Updates
A Study of Pembrolizumab and Cryoablation in People with Breast Cancer
NCT06246968
Recruiting
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Register for Updates
Treatment of Orthostatic Hypotension in SCI
NCT05839652
Recruiting
The purpose of this study is to identify the effects of non-pharmacological and pharmacological anti-hypotensive treatment interventions on orthostatic hemodynamic responses, symptoms of autonomic dysreflexia and orthostatic hypotension, and levels of fatigue and comfort in hypotensive individuals with SCI.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
09/27/2024
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Hypotension
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
09/27/2024
Locations: Atlantic Health System Morristown, Morristown, New Jersey
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
Drug Screening System Method Comparison
NCT06618183
Recruiting
Prospective, open-label, single-dose, randomized, multi-site performance evaluation of the accuracy and usability Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and "donors."
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/26/2024
Locations: CenExel HRI, Berlin, New Jersey
Conditions: Reagent Kits, Diagnostic
Register for Updates
Olorofim Aspergillus Infection Study
NCT05101187
Recruiting
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Rutgers RWJMS, New Brunswick, New Jersey
Conditions: Invasive Aspergillosis
Register for Updates
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
NCT04725994
Recruiting
This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Astera Cancer Care, East Brunswick, New Jersey
Conditions: Gastric Cancer
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
09/26/2024
Locations: Windsor Dermatology, East Windsor, New Jersey
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
The Role of Macrophage Activation in Lung Injury Following Ozone Exposure
NCT05794087
Recruiting
The purpose of the study is to better understand the mechanisms of lung injury from ozone exposure. Subjects will participate in two exposure sessions: filtered air and 0.2 ppm ozone. The exposure visits will be at least 2 weeks apart. Subjects will be asked to produce sputum through coughing after each exposure. The samples will be analyzed for macrophage activity.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
09/25/2024
Locations: Rutgers - EOHSI, Piscataway, New Jersey
Conditions: Air Pollution
Register for Updates
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
NCT06238648
Recruiting
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates